Cabonen Phase II Studie zu Cabozantinib bei fortgeschrittenem neuroendokrinem Tumor (Aktiv)
Zweitlinie oder später
CaboAveNEC A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3). (Aktiv)